NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Price Target & More

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings data on Tuesday, May, 1st. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.06. The biotechnology company had revenue of $69.16 million for the quarter, compared to analysts' expectations of $78.65 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The company's revenue for the quarter was up 32.6% on a year-over-year basis. During the same period last year, the business earned ($0.33) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

9 analysts have issued 1-year target prices for Ironwood Pharmaceuticals' shares. Their predictions range from $13.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $19.4444 in the next year. View Analyst Ratings for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 18,814,070 shares, a drop of 12.2% from the April 30th total of 21,438,253 shares. Based on an average daily volume of 1,695,797 shares, the short-interest ratio is presently 11.1 days. Approximately 13.7% of the company's stock are sold short. View Ironwood Pharmaceuticals' Current Options Chain.

Some companies that are related to Ironwood Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO) and FibroGen (FGEN).

Press coverage about IRWD stock has trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ironwood Pharmaceuticals earned a coverage optimism score of 0.22 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 47.45 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Ironwood Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (3.65%), OppenheimerFunds Inc. (1.70%), Northern Trust Corp (1.03%), Loomis Sayles & Co. L P (1.01%), Sector Gamma AS (0.74%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Artal Group S.A., State of Wisconsin Investment Board, Barclays PLC, Sector Gamma AS, Loomis Sayles & Co. L P, California Public Employees Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Julie Mchugh, Mark G Currie and Peter M Hecht. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, OppenheimerFunds Inc., UBS Group AG, Engineers Gate Manager LP, Point72 Asset Management L.P., Trexquant Investment LP, Schwab Charles Investment Management Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $19.34.

Ironwood Pharmaceuticals has a market capitalization of $2.83 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]